Latest Report on Sickle Cell Disease – Pipeline Review, H1 2020

Research By Markets adds Market Research Report - Latest Report on Sickle Cell Disease – Pipeline Review, H1 2020

For detailed information: https://www.researchbymarkets.com/report/sickle-cell-disease-pipeline-review-h1-2020-598547.html

Sickle Cell Disease – Pipeline Review, H1 2020

Summary

Sickle Cell Disease – Pipeline Review, H1 2020, provides an overview of the Sickle Cell Disease (Hematological Disorders) pipeline landscape.

Sickle cell anemia is a genetic (inherited) blood disorder in which red blood cells, which carry oxygen around the body, develop abnormally. Signs and symptoms include anemia, delayed growth, vision problems, pain and frequent infections. Treatment includes antibiotics, pain relievers, blood transfusion and stem cell transplant.

Report Highlights

Sickle Cell Disease – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Sickle Cell Disease (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sickle Cell Disease (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sickle Cell Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 9, 11, 4, 26 and 8 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 5 and 1 molecules, respectively.

Sickle Cell Disease (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Sickle Cell Disease (Hematological Disorders).
– The pipeline guide reviews pipeline therapeutics for Sickle Cell Disease (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Sickle Cell Disease (Hematological Disorders) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Sickle Cell Disease (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Sickle Cell Disease (Hematological Disorders)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Sickle Cell Disease (Hematological Disorders).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Sickle Cell Disease (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned:
Agios Pharmaceuticals Inc
Alkermes Plc
Angiocrine Bioscience Inc
Annexin Pharmaceuticals AB
Aruvant Sciences Inc
Axcella Health Inc
Beam Therapeutics Inc
bluebird bio Inc
Bristol-Myers Squibb Co
C4X Discovery Holdings Plc
Cannabis Science Inc
Cell Source Inc
Cetya Therapeutics Inc
CRISPR Therapeutics AG
CSL Ltd
Cyclerion Therapeutics Inc
Dystrogen Therapeutics SA
Editas Medicine Inc
Emmaus Life Sciences Inc
Epidestiny Inc
Epizyme Inc
Errant Gene Therapeutics LLC
ExCellThera Inc
Forma Therapeutics Inc
Fulcrum Therapeutics Inc
Functional Fluidics LLC
Gamida Cell Ltd
Gilead Sciences Inc
Global Blood Therapeutics Inc
Glycan Therapeutics Inc
Hillhurst Biopharmaceuticals Inc
Homology Medicines Inc
Imara Inc
Intellia Therapeutics Inc
Invenux LLC
Medeor Therapeutics Inc
Merck & Co Inc
Micelle BioPharma Inc
MimeTech Srl
Modus Therapeutics AB
Molecules For Health Inc
Novartis AG
Oryzon Genomics SA
PHD Biosciences
Phoenicia Biosciences Inc
Rare Partners Srl
Regenacy Pharmaceuticals LLC
ReNeuroGen LLC
Sangamo Therapeutics Inc
Secura Bio Inc
Syros Pharmaceuticals Inc
Tarus Therapeutics Inc
Trucode Gene Repair Inc
Vanguard Therapeutics Inc


For queries regarding this report: https://www.researchbymarkets.com/sample-request/598547

Contact Us:
ResearchByMarkets.com
Sales Desk
enquiry@researchbymarkets.com
https://www.researchbymarkets.com
https://www.researchbymarkets.com/aboutus

Follow us on Social Media:
Facebook: https://www.facebook.com/researchbymarkets/
LinkedIn: https://www.linkedin.com/company/researchmarkets
Twitter: https://twitter.com/ResearchByMrkts

Ritesh Tiwari is the Founder of Research By Markets, a leading Market Research Reports Reseller trusted by Fortune listed companies for their requirements of Syndicated and Custom Market Research Reports. Ritesh has an overall experience of 18+ years in Recruitments, Sales and Operations. He has been associated with the Market Research industry for the past 7 years. He is an avid foodie as well as a huge football fan being a supporter of Manchester United (EPL) and FC Barcelona (La Liga). Get in touch with him via ritesh@researchbymarkets.com. *Market Research News is a part of Research By Markets.